Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aytu Biopharma Inc AYTU

Healthcare
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended... see more

Recent & Breaking News (NDAQ:AYTU)

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Accesswire 8 days ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Accesswire November 6, 2024

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Accesswire October 14, 2024

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Accesswire October 1, 2024

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Accesswire September 26, 2024

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Accesswire September 16, 2024

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Accesswire August 8, 2024

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Accesswire August 6, 2024

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

Accesswire June 18, 2024

Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024

Newsfile May 29, 2024

Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Accesswire May 23, 2024

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Accesswire May 8, 2024

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Accesswire April 3, 2024

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Accesswire February 14, 2024

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Accesswire February 7, 2024

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Accesswire January 23, 2024

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Accesswire November 30, 2023

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Accesswire November 14, 2023

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Accesswire November 8, 2023

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Accesswire November 7, 2023